

Psychedelics.media Expands Editorial Coverage with the Launch of LeafLit.media



Melbourne, Victoria Jul 14, 2026 ([IssueWire.com](https://www.issuewire.com)) - *The Asia-Pacific's dedicated business publication for the psychedelic medicines industry now includes specialist medicinal cannabis business news, recognising the growing convergence between the two therapeutic sectors.*

Psychedelics.media, the Asia-Pacific's dedicated business publication for the psychedelic medicines industry, has expanded its editorial coverage with the launch of **LeafLit.media**, a specialist medicinal cannabis business news section now available on the Psychedelics.media platform.

The expansion reflects the growing convergence between medicinal cannabis and psychedelic medicine. As Australia's healthcare system embraces novel therapeutics, psychiatrists, general practitioners, psychologists, pharmacists and specialist clinics are increasingly engaging with both

fields. With psychedelic-assisted therapies continuing to develop through clinical research, regulatory reform and expanded treatment pathways, there is growing value in providing healthcare professionals with trusted coverage across both sectors.

LeafLit.media delivers independent reporting on Australia's regulated medicinal cannabis sector, publishing business news, ASX announcements, clinical research, regulation, pharmacy, telehealth, investment and international market developments.

The new section complements Psychedelics.media's existing coverage of psychedelic medicines, biotechnology, clinical trials, psychiatry, psychology, mental health innovation, public markets and industry intelligence, creating a broader editorial platform for professionals working across emerging therapeutic medicines.

"Medicinal cannabis and psychedelic medicines are increasingly part of the same clinical conversation," said **Gary Mackenzie, Editor of Psychedelics.media.**

"Many of the clinicians prescribing medicinal cannabis today are also closely following developments in psychedelic-assisted therapies through research, education and evolving models of care. As these therapies continue to expand in Australia, patients will increasingly move through the same healthcare ecosystem, creating greater overlap between prescribers, psychiatrists, psychologists, pharmacists, researchers and specialist clinics. By bringing LeafLit.media into Psychedelics.media, we're building a platform that reflects where healthcare and novel therapeutic medicines are heading, providing trusted business intelligence, clinical developments and regulatory news across both sectors."

Unlike consumer cannabis publications, LeafLit.media is focused exclusively on the professional market, delivering journalism for healthcare practitioners, psychiatrists, psychologists, pharmacists, clinic operators, researchers, pharmaceutical companies, investors and industry executives.

Editorial coverage includes:

- Medicinal cannabis business news
- ASX and global cannabis company announcements
- Clinical research and scientific developments
- Healthcare policy and regulation
- Pharmacy and prescribing
- Telehealth and clinic operations
- Investment and capital markets
- Manufacturing and pharmaceutical supply chains
- International market intelligence

The addition of LeafLit.media broadens Psychedelics.media's editorial offering while maintaining its primary focus on the rapidly evolving psychedelic medicines industry. It also creates a unified destination for professionals working across two of the fastest-evolving areas of therapeutic medicine, where innovation, regulation and clinical practice are increasingly intersecting.

Readers can now access dedicated reporting across both therapeutic sectors through a single platform designed to support informed decision-making across healthcare, research, investment and policy.

Visit [LeafLit.media](#):

<https://psychedelics.media/category/leafalit>

Media Contact

Leafalit.media

*****@psychedelics.media

<https://psychedelics.media/category/leafalit>

Source : Leafalit.media

[See on IssueWire](#)